Clinical Trials Directory

Trials / Terminated

TerminatedNCT02785822

Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.

Randomized, Single Blind, Prospective Clinical Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
Sex
Female
Age
18 Years – 38 Years
Healthy volunteers
Not accepted

Summary

Polycystic ovary occurs in 15-20% of the population will be submitted to TRA. Whether it is associated with other signs or symptoms (polycystic ovarian syndrome) as if presented in isolation, its therapeutic management has special connotations sometimes favoring the low response although the standard is the tendency to hyperresponsiveness. Although there are studies comparing the combination of FSH and LH and FSH in controlled hyperstimulation of these patients, there are no previous prospective randomized studies comparing administration of urinary FSH (hFSH-HP) with a combination of FSH and HCG (HMG HP). Therefore the aim of this study is to prove that both drugs are comparable in the treatment of these patients. The test substances are marketed in Spain (Fostipur and Meriofert, respectively) with an indication for use in these patients. In this study both medicines will be administered in a randomized way under the usual conditions in which it is used in routine clinical practice to compare the quantity of mature oocytes respect to the total oocytes obtained, as a primary outcome measure.

Conditions

Interventions

TypeNameDescription
DRUGhMG-HPOvarian stimulation with hMG-HP (150 IU / day)
DRUGhFSH-HPOvarian stimulation with hFSH-HP (150 IU / day)

Timeline

Start date
2017-02-23
Primary completion
2018-05-09
Completion
2018-05-09
First posted
2016-05-30
Last updated
2019-02-25

Locations

2 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT02785822. Inclusion in this directory is not an endorsement.